Bcl-XL represents a druggable molecular vulnerability during aurora B inhibitor-mediated polyploidization

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 28, 2010, Pages 12634-12639

  Shah, O Jameel ^a   Lin, Xiaoyu ^a   Li, Leiming ^a   Huang, Xiaoli ^a   Li, Junling ^a   Anderson, Mark G ^b   Tang, Hua ^b   Rodriguez, Luis E ^a   Warder, Scott E ^b   McLoughlin, Shaun ^b   Chen, Jun ^a   Palma, Joann ^a   Glaser, Keith B ^a   Donawho, Cherrie K ^a   Fesik, Stephen W ^a   Shen, Yu ^a  

^a Oncology Division   (United States)

^b ABBOTT LABORATORIES   (United States)

Author keywords

Apoptosis; Aurora kinase; Bcl XL; Polyploidy

Indexed keywords

4 [4 [2 (4 CHLOROPHENYL) 5,5 DIMETHYL 1 CYCLOHEXEN 1 YLMETHYL] 1 PIPERAZINYL] N [4 [3 MORPHOLINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 (TRIFLUOROMETHYLSULFONYL)BENZENESULFONYL]BENZAMIDE; AURORA B KINASE; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; MK 0547; PROTEIN BCL 2; PROTEIN BCL W; PROTEIN BCL XL; PROTEIN MCL 1; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VIVO STUDY; POLYPLOIDY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION;

ANILINE COMPOUNDS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; ENZYME INHIBITORS; MALE; MICE; NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; SULFONAMIDES;

EID: 77955452798     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0913615107     Document Type: Article

References (22)

1. Ruchaud S, Carmena M, Earnshaw WC (2007) Chromosomal passengers: Conducting cell division. Nat Rev Mol Cell Biol 8:798-812. (Pubitemid 47462135)
2. Gizatullin F, et al. (2006) The Aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function. Cancer Res 66:7668-7677.
3. Harrington EA, et al. (2004) VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 10:262-267.
4. Wilkinson RW, et al. (2007) AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis. Clin Cancer Res 13:3682-3688.
5. Yang J, et al. (2007) AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor inhumanacute leukemiacells invitroandinvivo. Blood110:2034-2040.
6. Rancati G, et al. (2008) Aneuploidy underlies rapid adaptive evolution of yeast cells deprived of a conserved cytokinesis motor. Cell 135:879-893.
7. Tse C, et al. (2008) ABT-263: A potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 68:3421-3428.
8. Shoemaker AR, et al. (2008) Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models. Clin Cancer Res 14:3268-3277.
9. Li J, et al. (2009) Inhibition of Aurora B kinase sensitizes a subset of human glioma cells to TRAIL concomitant with induction of TRAIL-R2. Cell Death Differ 16:498-511.
10. Manfredi MG, et al. (2007) Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase. Proc Natl Acad Sci USA 104:4106-4111.
11. Wei MC, et al. (2001) Proapoptotic BAX and BAK: A requisite gateway to mitochondrial dysfunction and death. Science 292:727-730.
12. Zong WX, Lindsten T, Ross AJ, MacGregor GR, Thompson CB (2001) BH3-only proteins that bind pro-survival Bcl-2 family members fail to induce apoptosis in the absence of Bax and Bak. Genes Dev 15:1481-1486. (Pubitemid 32552527)
13. Kim H, et al. (2006) Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies. Nat Cell Biol 8:1348-1358.
14. Willis SN, et al. (2007) Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 315:856-859. (Pubitemid 46264314)
15. Chen L, et al. (2005) Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 17:393-403.
16. Capaccioli S, et al. (1996) A bcl-2/IgH antisense transcript deregulates bcl-2 gene expression in human follicular lymphoma t(14;18) cell lines. Oncogene 13:105-115. (Pubitemid 26248550)
17. Klasa RJ, et al. (2000) Eradication of human non-Hodgkin's lymphoma in SCID mice by BCL-2 antisense oligonucleotides combined with low-dose cyclophosphamide. Clin Cancer Res 6:2492-2500.
18. Minn AJ, Boise LH, Thompson CB (1996) Expression of Bcl-xL and loss of p53 can cooperate to overcome a cell cycle checkpoint induced by mitotic spindle damage. Genes Dev 10:2621-2631.
19. Chen S, Dai Y, Harada H, Dent P, Grant S (2007) Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res 67:782-791.
20. Lin X, et al. (2007) 'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737. Oncogene 26:3972-3979.
21. van Delft MF, et al. (2006) The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 10:389-399.
22. Berenbaum MC (1981) Criteria for analyzing interactions between biologically active agents. Adv Cancer Res 35:269-335.